Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT05973487

Public ClinicalTrials.gov record NCT05973487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.

Study identification

NCT ID
NCT05973487
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
TScan Therapeutics, Inc.
Industry
Enrollment
840 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 6, 2024 (Actual)
Primary completion
Dec 30, 2026 (Estimated)
Completion
Dec 30, 2026 (Estimated)
Last update posted
Nov 17, 2025

2024 – 2026

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
HonorHealth Research and Innovation Institute Scottsdale Arizona 85258 —
University of California San Diego San Diego California 92037 —
Yale Cancer Center New Haven Connecticut 06510 —
Memorial Healthcare System Hollywood Florida 33021 —
University of Miami, Sylvester Comprehensive Cancer Center Miami Florida 33136 —
Orlando Health Orlando Florida 32806 —
University of South Florida Tampa Florida 33606 —
University of Chicago Chicago Illinois 60637 —
Norton Cancer Institute Louisville Kentucky 40202 —
Karmanos Cancer Institute Detroit Michigan 48201 —
University of Minnesota Masonic Cancer Center Minneapolis Minnesota 55455 —
Columbia University Herbert Irving Comprehensive Cancer Center New York New York 10032 —
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 —
Oncology Hematology Care Cincinnati Ohio 45242 —
The Cleveland Clinic Cleveland Ohio 44195 —
OU Health Stephenson Cancer Center Oklahoma City Oklahoma 73104 —
Providence Cancer Institute Franz Clinic Portland Oregon 97213 —
Allegheny Hospitals Network Pittsburgh Pennsylvania 15224 —
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 —
Sarah Cannon Research Institute Nashville Tennessee 37203 —
Baylor College of Medicine Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05973487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2025 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05973487 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →